Vertex Pharmaceuticals (VRTX) ended the recent trading session at $416.81, demonstrating a +2.01% change from the preceding day's closing price. The stock's performance was ahead of the S&P 500's ...

For two decades, US biotech Vertex (Nasdaq: VRTX) built a reputation as one of the few companies to pair cutting-edge science ...

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $407.9, denoting a -1.05% move from the preceding trading day.

Vertex Pharmaceuticals Incorporated has recently witnessed a notable change in its stock holdings, with Aberdeen Group plc ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Vertex Pharmaceuticals has been a clear winner in the pharmaceutical sector. Over the past two decades, this powerhouse has ...

Investing.com -- Stoke Therapeutics (NASDAQ:STOK) stock rose 7% Monday after the company announced the appointment of Ian F. Smith as its permanent Chief Executive Officer.

ClearBridge Investments, an investment management company, released its “ClearBridge Large Cap Growth Strategy” third-quarter 2025 investor letter. A copy of the letter can be downloaded here.

By stepping out as the first biopharma to win a three-year exemption from President Donald Trump’s earlier-announced plans for 100% tariffs, in return for agreeing to manufacture more of its drugs in ...

The company had to abandon the development of a medicine for type 1 diabetes (T1D), while another therapy in development for acute pain failed a phase 2 study. The biotech company also encountered ...

Fintel reports that on October 2, 2025, Citigroup maintained coverage of Vertex Pharmaceuticals (NasdaqGS:VRTX) with a Buy recommendation. Analyst Price Forecast Suggests 19.95% Upside As of September ...